A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...
Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...
Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...
Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.
The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...
Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.
Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.
New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...
An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.